31 An animal model of intrathecal bevacizumab for LM provided safety data to allow the use of bevacizumab in people with treatment\refractory LM in phase I/II studies in the category
31 An animal model of intrathecal bevacizumab for LM provided safety data to allow the use of bevacizumab in people with treatment\refractory LM in phase I/II studies in the category. LM was diagnosed, 12 (85.7%) patients had clinical symptoms, 71.4% (10/14) of patients were diagnosed with LM by cytology, and five (35.7%) patients had a…